Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.

@article{Maisey2002MulticenterRP,
  title={Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.},
  author={Nick R Maisey and Ian Chau and D. Hamish Cunningham and Andrew T. Norman and Matt T Seymour and Tamas Hickish and Tim Iveson and Mary O'brien and Niall C. Tebbutt and Angela Harrington and Mark Hill},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 14},
  pages={3130-6}
}
PURPOSE To compare protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin (MMC) in patients with advanced pancreatic cancer in a multicenter, prospectively randomized study. PATIENTS AND METHODS Two hundred eight patients were randomized to PVI 5-FU (300 mg/m(2)/d for a maximum of 24 weeks) or PVI 5-FU plus MMC (7 mg/m(2) every 6 weeks for four courses). The major end points were tumor response, survival, toxicity, and quality of life (QOL). RESULTS The two… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2016

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2016

Similar Papers

Loading similar papers…